Dose Escalation Study Using Proton Beam Radiotherapy for Hepatocellular Carcinoma

Carcinoma, Hepatocellular Clinical Trial

Official title: A Phase I Dose Escalation Study Using Proton Beam Radiotherapy for Hepatocellular Carcinoma

Status Completed

Clinical Trial Summary

The radical treatment for Hepatocellular carcinoma (HCC) is surgery. However, it is only for 10 to 20% of all patients and 10 to 30% of them have relapsed every year after surgery. For an inoperable case, we can consider Liver transplantation. But there is not enough organ donor and it is very expensive. In that case, various treatment modalities for HCC (i.e., transcatheter arterial embolization [TAE] and percutaneous ethanol injection [PEI], radiofrequency ablation etc.) have become clinically available. In addition, after these treatment, radiation therapy can be conducted as a combined treatment. If it is difficult, radiation therapy can be conducted alone. In this case, radiation therapy can use fractionated stereotactic radiation therapy [FSRT] or 3D simulation to minimize the exposure to normal tissues. In recent years, Proton therapy is a new radiation therapy which remaining energy is released when they reach the tumor, delivering the most effective dose of radiation. The purpose of this trial is to improve the therapeutic effects by using proton therapy.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular

• NCT number: NCT00662246
• Study type: Interventional
• Source: National Cancer Center, Korea
• Status: Completed
• Phase: Phase 1
• Start date: January 2007
• Completion date: March 2010